Congruence Therapeutics Overview

  • Founded
  • 2021
Founded
  • Status
  • Private
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $50M
Latest Deal Amount
  • Investors
  • 7

Congruence Therapeutics General Information

Description

Developer of a pharmacological stabilizer intended for the treatment of rare diseases. The company uses the interface of computational and experimental drug discovery, structural bioinformatics, computational chemistry, and machine learning to deploy an in silico platform that enables the design of a validated class of small molecules, helping researchers to design novel small molecules for diseases of protein misfolding.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Montreal, Quebec
  • Canada
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Congruence Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 08-Feb-2022 $50M 0000 Completed Startup
To view Congruence Therapeutics’s complete valuation and funding history, request access »

Congruence Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Clarissa Desjardins Ph.D Co-Founder & Chief Executive Officer
Kenneth Valenzano Ph.D Chief Scientific Officer
Michael Goldsmith Ph.D Co-Founder & Chief Innovation Officer
Charles Grubsztajn Chief Operating Officer
To view Congruence Therapeutics’s complete executive team members history, request access »

Congruence Therapeutics Board Members (1)

Name Representing Role Since
Nancy Harrison Congruence Therapeutics Board Member 000 0000
To view Congruence Therapeutics’s complete board members history, request access »

Congruence Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Congruence Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amplitude Ventures Venture Capital Minority 000 0000 000000 0
Clarissa Desjardins Angel (individual) Minority 000 0000 000000 0
Driehaus Capital Management Corporation Minority 000 0000 000000 0
Fonds de solidarité FTQ PE/Buyout Minority 000 0000 000000 0
Investissement Québec Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »